EP Patent

EP2371357A1 — Oral formulations and lipophilic salts of methylnaltrexone

Assigned to Wyeth LLC · Expires 2011-10-05 · 15y expired

What this patent protects

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

USPTO Abstract

The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration.

Drugs covered by this patent

Patent Metadata

Patent number
EP2371357A1
Jurisdiction
EP
Classification
—
Expires
2011-10-05
Drug substance claim
No
Drug product claim
No
Assignee
Wyeth LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.